Truist Financial Issues Pessimistic Forecast for Humana (NYSE:HUM) Stock Price

Humana (NYSE:HUM) had its price objective lowered by Truist Financial from $300.00 to $285.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “hold” rating on the insurance provider’s stock. Truist Financial’s target price suggests a potential upside of 17.34% from the stock’s current price.

Other analysts also recently issued reports about the stock. Piper Sandler cut their price objective on shares of Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a research report on Thursday, July 31st. Morgan Stanley reduced their price target on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a research report on Thursday, July 31st. Mizuho increased their target price on Humana from $300.00 to $345.00 and gave the company an “outperform” rating in a research note on Thursday, October 9th. Royal Bank Of Canada lifted their target price on Humana from $283.00 to $322.00 and gave the stock an “outperform” rating in a report on Thursday, August 21st. Finally, Robert W. Baird lowered their price target on Humana from $300.00 to $297.00 and set a “neutral” rating on the stock in a report on Friday, July 25th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $298.39.

Humana Stock Down 3.6%

Shares of NYSE HUM traded down $9.16 on Monday, reaching $242.89. 562,150 shares of the company’s stock traded hands, compared to its average volume of 1,762,685. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a market cap of $29.21 billion, a price-to-earnings ratio of 18.64, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. The business’s 50 day simple moving average is $278.04 and its two-hundred day simple moving average is $258.86. Humana has a 12 month low of $206.87 and a 12 month high of $315.35.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.29. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business had revenue of $32.65 billion during the quarter, compared to analysts’ expectations of $31.99 billion. During the same quarter in the previous year, the business earned $4.16 earnings per share. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. As a group, equities research analysts forecast that Humana will post 16.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Humana

A number of institutional investors have recently bought and sold shares of HUM. Factorial Partners LLC bought a new position in shares of Humana in the third quarter worth about $781,000. Stevens Capital Management LP bought a new position in Humana in the 3rd quarter worth approximately $629,000. Raiffeisen Bank International AG raised its position in shares of Humana by 4.8% during the third quarter. Raiffeisen Bank International AG now owns 7,132 shares of the insurance provider’s stock valued at $1,820,000 after buying an additional 324 shares during the last quarter. AMG National Trust Bank raised its position in shares of Humana by 106.5% during the third quarter. AMG National Trust Bank now owns 16,953 shares of the insurance provider’s stock valued at $4,411,000 after buying an additional 8,744 shares during the last quarter. Finally, Bridgewater Advisors Inc. lifted its holdings in shares of Humana by 9.1% in the third quarter. Bridgewater Advisors Inc. now owns 1,131 shares of the insurance provider’s stock worth $284,000 after buying an additional 94 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.